UCB SA

OTCPK:UCBJ.F Stock Report

Market Cap: US$59.5b

UCB Valuation

Is UCBJ.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of UCBJ.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: UCBJ.F ($326.39) is trading below our estimate of future cash flow value ($673.74)

Significantly Below Future Cash Flow Value: UCBJ.F is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for UCBJ.F?

Key metric: As UCBJ.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for UCBJ.F. This is calculated by dividing UCBJ.F's market cap by their current earnings.
What is UCBJ.F's PE Ratio?
PE Ratio32.7x
Earnings€1.56b
Market Cap€50.98b

Price to Earnings Ratio vs Peers

How does UCBJ.F's PE Ratio compare to its peers?

The above table shows the PE ratio for UCBJ.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average22x
ZTS Zoetis
18.9x6.29%US$49.3b
TEVA Teva Pharmaceutical Industries
25.2x8.74%US$34.2b
BMY Bristol-Myers Squibb
17.1x1.46%US$117.7b
RPRX Royalty Pharma
26.6x10.04%US$27.0b
UCBJ.F UCB
32.7x17.31%US$51.0b

Price-To-Earnings vs Peers: UCBJ.F is expensive based on its Price-To-Earnings Ratio (32.7x) compared to the peer average (22x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does UCBJ.F's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

6 CompaniesPrice / EarningsEstimated GrowthMarket Cap
NDOI Endo
0.3xn/aUS$1.76b
ORMP Oramed Pharmaceuticals
2.2xn/aUS$142.37m
BTMD biote
1.7x-77.82%US$55.53m
OWPC One World Products
0.3xn/aUS$920.44k
UCBJ.F 32.7xIndustry Avg. 16.9xNo. of Companies6PE01020304050+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: UCBJ.F is expensive based on its Price-To-Earnings Ratio (32.7x) compared to the US Pharmaceuticals industry average (16.5x).

Price to Earnings Ratio vs Fair Ratio

What is UCBJ.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

UCBJ.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio32.7x
Fair PE Ratio28.5x

Price-To-Earnings vs Fair Ratio: UCBJ.F is expensive based on its Price-To-Earnings Ratio (32.7x) compared to the estimated Fair Price-To-Earnings Ratio (28.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst UCBJ.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$326.39
US$329.68
+1.01%
12.87%US$393.79US$225.85n/a20
Apr ’27US$320.14
US$329.68
+2.98%
12.87%US$393.79US$225.85n/a20
Mar ’27US$306.00
US$335.03
+9.49%
13.66%US$401.94US$212.79n/a20
Feb ’27US$315.04
US$315.63
+0.19%
16.43%US$370.33US$175.61n/a19
Jan ’27US$293.58
US$310.97
+5.92%
11.84%US$352.49US$211.49n/a18
Dec ’26US$288.89
US$295.47
+2.28%
13.42%US$346.86US$184.99n/a18
Nov ’26US$265.96
US$293.31
+10.28%
13.95%US$345.82US$184.44n/a18
Oct ’26US$294.18
US$276.60
-5.97%
10.60%US$316.98US$187.84n/a18
Sep ’26US$239.04
US$262.58
+9.85%
11.49%US$298.70US$187.42n/a18
Aug ’26US$213.80
US$252.62
+18.16%
11.75%US$295.28US$185.27n/a18
Jul ’26US$199.89
US$249.25
+24.69%
12.57%US$294.74US$159.16n/a17
Jun ’26US$179.39
US$236.65
+31.92%
12.89%US$283.83US$153.27n/a18
May ’26n/a
US$237.19
0%
12.89%US$284.48US$153.62n/a18
Apr ’26US$172.33
US$227.54
+32.04%
11.85%US$268.82US$145.16US$320.1418
Mar ’26US$186.78
US$216.99
+16.18%
13.60%US$259.28US$140.01US$306.0018
Feb ’26US$195.25
US$202.55
+3.74%
22.92%US$262.22US$103.84US$315.0418
Jan ’26US$197.03
US$201.79
+2.42%
22.54%US$263.74US$104.44US$293.5818
Dec ’25n/a
US$188.74
0%
22.84%US$262.38US$103.90US$288.8918
Nov ’25n/a
US$185.61
0%
20.74%US$270.91US$107.28US$265.9618
Oct ’25n/a
US$182.93
0%
16.51%US$221.39US$109.59US$294.1819
Sep ’25US$177.61
US$182.47
+2.74%
16.47%US$222.52US$110.15US$239.0419
Aug ’25n/a
US$168.51
0%
16.40%US$215.82US$106.83US$213.8019
Jul ’25n/a
US$149.72
0%
14.62%US$182.19US$106.10US$199.8919
Jun ’25n/a
US$138.30
0%
16.04%US$180.30US$76.03US$179.3919
May ’25US$133.68
US$134.97
+0.97%
15.82%US$175.06US$74.72n/a19
Apr ’25US$122.00
US$127.56
+4.56%
17.71%US$176.15US$75.19US$172.3319
US$346.93
Fair Value
5.9% undervalued intrinsic discount
20
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/08 10:57
End of Day Share Price 2026/04/08 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

UCB SA is covered by 37 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian BourdotBarclays
Charles PitmanBarclays
Charles PitmanBarclays